End points for therapeutic trials for BPD

Judy L. Aschner, Cynthia C.T. McEvoy

Research output: Chapter in Book/Report/Conference proceedingChapter


Drug development for bronchopulmonary dysplasia (BPD) prevention and treatment has been hampered by definitions that are inconsistently applied and are only modestly correlated with post hospital discharge outcomes that are important to families and relevant to life-long lung health. Development and validation of early predictive biomarkers to better target and individualize therapies will advance intervention trials. A respiratory scoring system prior to hospital discharge that reflects parenchymal disease severity, incorporates contemporary practices, has high sensitivity and specificity for longer term endpoints that are acceptable to regulatory agencies and meaningful to clinicians and families will accelerate therapeutic discovery.

Original languageEnglish (US)
Title of host publicationTantalizing Therapeutics in Bronchopulmonary Dysplasia
Number of pages16
ISBN (Electronic)9780128189870
ISBN (Print)9780128189917
StatePublished - Jan 1 2020


  • Biomarkers
  • Bronchopulmonary dysplasia
  • Clinical trials
  • Endpoints
  • Pulmonary function tests
  • Respiratory outcomes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'End points for therapeutic trials for BPD'. Together they form a unique fingerprint.

Cite this